Takeda Pharma ordered to pay $2.5 billion in Amitiza case

US federal jury finds Japanese drugmaker liable for anticompetitive agreement delaying generic version of constipation drug Amitiza

Mycenax and Spera forge alliance to streamline ADC drug substance

Lupin inks licensing agreement with Takeda to commercialize Vonoprazan

Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India

Alkem signs license agreement with Takeda to commercialise Vonoprazan in India

Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)

Zydus signs patent licensing agreement with Takeda for 'VaultA’ in India

The pooled prevalence of GERD in the Indian population is 15.6 %

Dr. Reddy's signs non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan

Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India

Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders

Takeda showcases digital health solutions at G20 Meeting in India

Showcased digital innovations: MyPKFit, SYNAPSE and Athena at the G20 Health Working Group Meeting

Future Packaging to redefine India Pharm industry growth: InnoPack Pharma

The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.

Strengthening the access to rare disease treatment in India

Takeda and United Nations Global Compact Network of India (UNGCNI) join hands